Results 171 to 180 of about 22,935 (284)

Association of SGLT2 inhibitors use with a lower risk of biliary diseases in patients with type 2 diabetes mellitus: a retrospective cohort study. [PDF]

Ann Med
Gao M, Lin Q, Hu K, Zhong B, Zhu T, Gong Z, Zhang K, Chen X, Chen X, Zhang Y, Li Y, Tang S, Su D, Liang X, Liu Y.   +14 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, Volume 34, Issue S2, Page 75-87, September 2026.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

BMJ Open Diabetes Res Care
Sklepinski S, Ratzki-Leewing AA, Herrin J, Swarna KS, Deng Y, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG.   +15 more
europepmc   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, Volume 34, Issue S2, Page 25-35, September 2026.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

Hepatogenous diabetes in the era of precision medicine: diagnosis, management, and future directions. [PDF]

Clin Exp Med
El-Azab G, Rady MA, Assem M, Nagdy H.
europepmc   +1 more source

Development and Clinical Utility of Machine Learning Models for Prediction of Same‐Day Discharge in Outpatient Hip and Knee Replacement: A Prognostic Study

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 8, September 2026.
ABSTRACT Background Hip and knee replacement are common procedures with an increasing focus on same‐day surgery. However, capacity constraints limit the number of eligible patients actually being scheduled for same‐day discharge, calling for further selection of those with the highest likelihood of same‐day discharge.
Christoffer C. Jørgensen, Jakob B. Frederiksen, Henrik Kehlet, Martin Lindberg‐Larsen, Kirill Gromov, Claus Varnum, Thomas Jakobsen, Manuel Josef Bieder, Mikkel Rathsach Andersen, Søren Overgaard, Torben B. Hansen, Troels Petersen   +11 more
wiley   +1 more source

Glaucoma Risk with Metformin and Sulfonylurea Therapies in Type 2 Diabetes: A Retrospective Cohort Study. [PDF]

Clin Ophthalmol
Lim J, Zhou J, Wu H, Liu Z, Lee DA.
europepmc   +1 more source

Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets

Annals of Human Genetics, Volume 90, Issue 5, Page 294-302, September 2026.
ABSTRACT Aims There is no proven treatment to prevent the growth or rupture of abdominal aortic aneurysm (AAA). As an aneurysm enlarges over time, the risk of fatal aortic rupture increases. Metformin, a drug usually prescribed to treat Type 2 diabetes, has previously been associated with reduced AAA risk in observational studies. Our aim was to assess
Katie Louise Saxby, Svetlana Stoma, Frank Dudbridge, Nilesh J. Samani, Matthew J. Bown, Christopher P. Nelson   +5 more
wiley   +1 more source

Effectiveness of empagliflozin in reducing hypoglycemic events as compared to sulfonylurea in type 2 diabetes patients during fasting in Ramadan: a single-center study. [PDF]

BMC Endocr Disord
Kiran Z, Fatima N, Baloch AA, Shaikh KUS, Hasan SM, Khan MU.   +5 more
europepmc   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, Volume 14, Issue 6, Page 1627-1635, September 2026.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source